Search clinical trials for: Proteinase Inhibitory Proteins, Secretory

Total 14764 results

Octapharma

Withdrawn

Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency

Alpha 1-Antitrypsin Deficiency
Medical University Innsbruck

Completed

Argatroban in Critically Ill Patients With Heparin Resistance

Achievement of a Sufficient Thrombosis Prohpylaxis in Clitically Ill Patients With Heparin Resistance

Austria
Sherief Abd-Elsalam

Unknown

Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis

Portal Vein Thrombosis

Egypt
Astellas Pharma Inc

Completed

A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150

Healthy | Pharmacokinetics of YM150

Japan
The First Hospital of Jilin University

Not yet recruiting

Neutrophil Elastase Inhibitor in Treatment of ARDS Patients With Mechanical Ventilation Caused by Sepsis

Acute Respiratory Distress Syndrome
BioCryst Pharmaceuticals

Completed

Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE (APeX-2)

Hereditary Angioedema | HAE

United States, Austria, Canada, Czechia, France, Germany, Hungary, North Macedonia, Romania, Spain, United Kingdom
Westfälische Wilhelms-Universität Münster
German Research Foundation

Completed

Reducing Acute Kidney Injury Occurence by Administering Angiotensin II (AIDED)

Cardiac Surgery | Vasoplegia | Hyperreninemia

Germany
Asan Medical Center

Completed

Antithrombin III and Post-liver Transplantation Acute Kidney Injury

Liver Transplantation and Antithrombin

Korea, Republic of
Boehringer Ingelheim

Completed

A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)

Thromboembolism

Spain, Germany, India, Italy, Netherlands, Portugal, France, Poland, Russian Federation
Boehringer Ingelheim

Completed

Bioequivalence of Tablet Formulation of Dabigatran Etexilate Compared to Commercial Capsule Formulation Following Oral Administration in Healthy Male Subjects

Healthy

Japan
Vanderbilt University Medical Center

Completed

The Renin-Aldosterone Axis in Postural Tachycardia Syndrome

Postural Orthostatic Tachycardia Syndrome (POTS)

United States
Vanderbilt University

Withdrawn

Intracoronary Bradykinin Mediated t-PA Release in Heart Transplant Recipients (P1A4D)

Heart Transplantation

United States
Boehringer Ingelheim

Completed

Pharmacokinetic (PK) Assessment of BIBR 1048 in Patients After Primary Elective Total Hip Replacement Surgery

Venous Thromboembolism
Deutsches Herzzentrum Muenchen

Completed

Impact of Dabigatran and Phenprocoumon on ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation (Dabi-ADP-1)

Atrial Fibrillation

Germany
National Institute of Cardiovascular Diseases,...

Recruiting

Rivaroxaban in Left Ventricular Thrombus

Acute Coronary Syndrome | Left Ventricular Thrombus

Pakistan
Peking University Third Hospital
Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University and other collaborators

Completed

Prevention of Ulinastatin on Acute Respiratory Distress Syndrome (ARDS)

Critical Illness | Acute Respiratory Distress Syndrome

China
Assistance Publique - Hôpitaux de Paris

Active, not recruiting

Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension (APIS)

Intrahepatic Non Cirrhotic Portal Hypertension

France
Pfizer

Completed

Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data

Non-valvular Atrial Fibrillation

Japan
Brigham and Women's Hospital

Completed

Replication of the ARISTOTLE Anticoagulant Trial in Healthcare Claims Data

Atrial Fibrillation

United States
University of Padova

Completed

Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy (ERIKA)

Venous Thromboembolism | Haemorrhage

Italy
Bristol-Myers Squibb
Pfizer

Completed

Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder

Thromboembolism

United States, Canada, Mexico, Israel, Australia
Massachusetts General Hospital
Bristol-Myers Squibb

Terminated

Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)

Heparin-induced Thrombocytopenia | Heparin-induced Thrombocytopenia and Thrombosis

United States
Indiana University
Bristol-Myers Squibb; Pfizer; Janssen Pharmaceuticals

Completed

Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism (MATHVTE)

Venous Thromboembolism

United States
Dr Carlo Lavalle
Istituto Nazionale per le Ricerche Cardiovascolari (INRC)

Unknown

Italian Registry In the Setting of AF Ablation With Rivaroxaban (IRIS) (IRIS)

Atrial Fibrillation

Italy
University of North Carolina, Chapel Hill
North Carolina Translational and Clinical Sciences Institute

Completed

Pharmacokinetics of Apixaban in Nephrotic Syndrome

Proteinuria | Nephrotic Syndrome

United States
Daiichi Sankyo, Inc.

Completed

Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement

Thrombosis | Arthroplasty, Replacement, Hip

United States
Universitaire Ziekenhuizen KU Leuven
Bristol-Myers Squibb

Completed

Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study

ESRD | Anticoagulant Toxicity

Belgium
St. Joseph's Healthcare Hamilton
Bayer; University of Alberta; The Ottawa Hospital; Hamilton Health Sciences Corporation and other collaborators

Completed

Rivaroxaban for Antiphospholipid Antibody Syndrome (RAPS)

Antiphospholipid Antibody Syndrome

Canada
Ortho-McNeil Janssen Scientific Affairs, LLC
Bayer

Completed

Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement

Arthritis | Osteoarthritis, Knee | Thromboembolism | Osteoarthritis, Hip

United States
State University of New York - Upstate Medical...

Terminated

Rivaroxaban Effects in Subjects Who Have Undergone Gastric Bypass Surgery

Gastric Bypass Status

United States
Mayo Clinic

Completed

Cystatin-C C-guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project

Sepsis | Critical Illness | Methicillin-resistant Staphylococcus Aureus
Beijing Suncadia Pharmaceuticals Co., Ltd

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery

Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
Hong Kong WD Pharmaceutical Co., Limited

Unknown

A Single Dose Bioequivalence Study of WD-1602 Versus Pradaxa® in Healthy Subjects Under Fed Condition

Anticoagulant
Jatupon Kongtharvonskul
Police General Hospital

Completed

Comparative Outcomes Between Foot Cast and Short Leg Cast in the Patients With Acute Closed Fracture of Proximal Fifth Metatarsal (Zone II)

Acute Closed Fracture of Proximal Fifth Metatarsal (Zone II)

Thailand
Hospital Mutua de Terrassa

Unknown

Dabigatran Study in the Early Phase of Stroke. New Neuroimaging Markers and Biomarkers Study (SEDMAN STUDY) (SEDMAN)

Cardioembolic Stroke

Spain
Capital Medical University

Unknown

The Efficacy and Safety of Dabigatran Etexilate for the Treatment of Cerebral Venous Thrombosis

Cerebral Venous Thrombosis

China
Vanderbilt University

Terminated

Characterization of Brachial Arterial t-PA Release, Endothelial Function, Obesity and Inflammation (P1A3B)

Obesity

United States
University College, London

Unknown

The Coagulation Cascade in Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis | Interstitial Lung Disease | IPF
Vanderbilt University

Withdrawn

Brachial Artery t-PA Release in Heart Transplant Recipients (P1A3C)

Heart Transplantation

United States
Boehringer Ingelheim

Withdrawn

Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age

Venous Thromboembolism

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of Dabigatran Capsules, Pellets and Oral Solution in Healthy Volunteers

Healthy

Germany
University of Edinburgh

Completed

Interaction of Apelin and Angiotensin in the Systemic Circulation

Renin Angiotensin System

United Kingdom
Nantes University Hospital

Terminated

Effects (Long Term Analysis) of an Hyperproteinic Nutrition on Neonates With Intra-uterine Growth Delay : a Prospective, Multicentric , Randomized, Double Blind Study ("Proneonat") (Proneonat)

Intra-uterine Growth Delay

France
First Affiliated Hospital Xi'an Jiaotong University

Not yet recruiting

Improvement of Pulmonary Insufficiency After Aortic Dissection With Sivelestat Sodium (IPIADSS)

Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | Aortic Dissection

China
Ain Shams University

Completed

Role of NGAL and Cystatin C in Prediction of Acute Kidney Injury Covid-19 Infection

Biochemical Markers ,NGAL,Cystatin c, Acute Kidneyinjury, Covid 19

Egypt
Boehringer Ingelheim

Completed

Patients' Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation

Atrial Fibrillation

Taiwan
Boehringer Ingelheim

Completed

Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan

Atrial Fibrillation

Japan
Boehringer Ingelheim

Completed

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Venous Thromboembolism

Italy, Thailand, Russian Federation, Canada, Lithuania, Switzerland
Boehringer Ingelheim

Completed

A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin

Atrial Fibrillation

Japan
Medical College of Wisconsin

Completed

Gluten and Amylase Trypsin Inhibitors (ATI) Free Diet

Type1diabetes

United States

Search clinical trials for: Proteinase Inhibitory Proteins, Secretory

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations